Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657359 | 0.89 | ABL1 (0.49) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL3664080 | 0.84 | ABL1 (0.49) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL3659978 | 0.83 | ABL1 (0.52) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL3658773 | 0.83 | ABL1 (0.50) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975231 | 0.82 | NPC1 (0.40) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3664024 | 0.81 | ABL1 (0.52) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL12630368 | 0.76 | ABL1 (0.42) | ABL1 | |
| SCHEMBL3661487 | 0.75 | ABL1 (0.57) | ABL1NPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL12630383 | 0.75 | ABL1 (0.41) | ABL1 | |
| SCHEMBL8997525 | 0.74 | ABL1 (0.40) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231653-B1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2013-04-03 | — | — | EP | claimed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | claimed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | ABL1 294/4885NPC1 1397/4885RAB9A 845/4885 |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | NEK6, NEK1, TXK | ABL1 89/4885NPC1 2672/4885RAB9A 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.